Under construction – not a live service
Sign in
Taking people in ChinaNo phase

Growing lung stem cells from people with COPD in the lab

Researchers collect lung cells during bronchoscopy to grow lung organoids from adults with COPD.

Plain-language title generated from the registry record
Registry title: Establishment of Human Lung Stem Cell Proliferation System and Organoid Construction in COPD

Key facts

Where
Beijing, ChinaSee the site

Could this be for you?

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 55 years old?

Source: NCT06275230, who can take part

Where in China

  • China-Japan Friendship HospitalBeijing, ChinaTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
China-Japan Friendship Hospital
Trial code
NCT06275230
Record updated
10 February 2025
Original description
The goal of this study is to proliferate human lung stem cell in vitro in order to establish a lung organoid derived from patients with COPD. The main question it aims to answer are:Read full original descriptionShow less

Establishment of Human Lung Stem Cell Proliferation System and Organoid Construction in Chronic Obstructive Pulmonary Disease

The goal of this study is to proliferate human lung stem cell in vitro in order to establish a lung organoid derived from patients with COPD. The main question it aims to answer are:

* Can human lung stem cell proliferate in vitro. * Can a lung organoid derived from patients with COPD be established. Participants will be sampled during pulmonary bronchoscope for organoid establishment.

Inclusion: 1. Age under 55, regardless of gender; 2. Patients with COPD lung disease who are going to undergo bronchoscopic biopsy; 3. No genetic diseases and other respiratory diseases.

Exclusion: Other conditions determined by the investigators to be unsuitable for inclusion, such as difficult sampling, difficult follow-up, and complicated with other serious diseases.

ClinicalTrials.gov NCT06275230